Form 8-K NUVASIVE INC For: Dec 10
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 10, 2015
NUVASIVE, INC.
(Exact name of registrant as specified in its charter)
Delaware | 000-50744 | 33-0768598 | ||
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification Number) |
7475 Lusk Boulevard, San Diego, California 92121
(Address of principal executive offices) (Zip Code)
(858) 909-1800
(Registrants telephone number, including area code)
n/a
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):
¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 8.01 | Other Events. |
On December 10, 2015, NuVasive, Inc. (the Company) issued a press release announcing that it had selected a site for the build-out of the Companys new medical device manufacturing facility. A copy of this press release is furnished as Exhibit 99.1 hereto.
Item 9.01 | Financial Statements and Exhibits. |
(d) | Exhibits. |
99.1 | Press release issued by NuVasive, Inc. on December 10, 2015. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
NUVASIVE, INC. | ||
By: | /s/ Jason D. Hanson | |
Jason D. Hanson | ||
Executive Vice President, Strategy, Corporate Development and General Counsel |
Date: December 10, 2015
EXHIBIT INDEX
Exhibit Number |
Description | |
99.1 | Press release issued by NuVasive, Inc. on December 10, 2015. |
Exhibit 99.1
NEWS RELEASE
Investor/Media Contact:
Stacy Roughan
NuVasive, Inc.
1-858-909-1812
NUVASIVE ANNOUNCES LOCATION FOR NEW STATE-OF-THE-ART
MANUFACTURING FACILITY
SAN DIEGO, CA December 10, 2015 NuVasive, Inc. (NASDAQ: NUVA), a leading medical device company focused on transforming spine surgery with minimally disruptive, procedurally-integrated solutions, today announced that the Company has selected a site in West Carrollton, Ohio as the location for the build-out of its new medical device facility dedicated to spinal implant and instrument manufacturing. As first announced in August 2015, this new facility would support the Companys efforts to increase its internal manufacturing capabilities alongside its existing manufacturing facility in Dayton, Ohio, and enhance its focus on operational excellence.
NuVasive has entered into an agreement to acquire the manufacturing site and plans to invest approximately $45 million over the next 24 months to build-out and equip the new facility. The 160,000 square foot facility is currently scheduled to begin commercial scale production by year-end 2016. Subject to customary closing conditions, NuVasive expects to complete the acquisition of the site by the end of the year. NuVasive also is in the process of finalizing a package of incentives that reflects a continued partnership between the Company and the state of Ohio.
When at full scale, the new facility is expected to employ approximately 300 full-time, high-tech positions, including engineers and skilled machinists, as well as process development and validation specialists who will work with the Companys research and development teams to optimize and accelerate product launches. The new facility will house state-of-the-art equipment, including approximately 100 computer numerical control (CNC) machine tools and CMM inspection equipment, as well as clean-room operations.
Gregory T. Lucier, NuVasives Chairman and Chief Executive Officer, said, We are happy to announce that we have selected a site in West Carrollton, Ohio as the location for our new medical device manufacturing facility. The site selection and subsequent build-out is a major step forward in our efforts to enhance our manufacturing presence in the United States to support the self-manufacture of nearly 100% of select spinal products and instruments. With this new facility and our longer-term plans to also expand our manufacturing footprint globally, we expect to increase customer responsiveness, dramatically improve inventory turns and speed up design time velocity to more efficiently meet the growing demand for our innovative spine technology.
Our Ohio workforce is a critical part of our ongoing success and we are excited to expand our footprint and provide additional opportunities within the state. We greatly appreciate the support and cooperation of the Dayton Development Coalition and JobsOhio, as well as officials from both Montgomery County and the city of West Carrollton during the site selection process. I would like to personally thank Governor John R. Kasich and his office for their commitment to support incentives for NuVasive as we build out the new facility and train our expanded pool of employees who will support our growth in the region. NuVasive is well-known for our cutting-edge products and procedures and we look forward to building on this partnership and investing in the local community for years to come.
After an extensive search, we are thrilled NuVasive chose to expand their U.S. manufacturing asset in the Dayton region, said Jeff Hoagland, President and Chief Executive Officer of the Dayton Development Coalition. NuVasives investments in this new facility will retain and create hundreds of jobs for the region and support future development. Working together collaboratively with NuVasive and our community partners provided the support the Company needed to stay in the Dayton region and continue to grow.
NuVasives plan to remain in the Dayton region will enable our community to keep roughly a hundred existing jobs with plans to add nearly 200 more, said Debbie Lieberman, Montgomery County Commission President. The areas supply of a qualified workforce, various incentives and the efforts from a partnership between JobsOhio, the Dayton Development Coalition, Montgomery and Greene Counties and various local municipalities, have proven to be a deciding factor in the Companys decision to remain in the region.
West Carrollton is pleased to become the home of one of the largest advanced manufacturing facilities in southwest Ohio, said Mayor Jeff Sanner. We look forward to welcoming NuVasive to our community.
About NuVasive
NuVasive is an innovative global medical device company that is transforming spine surgery with minimally disruptive surgical products and procedurally-integrated solutions for the spine. NuVasive has emerged from a small startup to become the #3 player in the $9 billion global spine market and remains focused on market share-taking strategies as the Company continues on its path to become the industrys leading spine company. NuVasive offers a comprehensive spine portfolio of more than 90 unique products developed to improve spine surgery and patient outcomes. The Companys principal procedural solution is its Maximum Access Surgery, or MAS®, platform for lateral spine fusion. MAS was designed to provide safe, reproducible, and clinically proven outcomes, and is a highly differentiated solution with fully integrated neuromonitoring, customizable exposure, and a broad offering of application-specific implants and fixation devices designed to address a variety of pathologies.
NuVasive cautions you that statements included in this news release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasives results to differ materially from historical results or those expressed or implied by such forward-looking statements. Forward-looking statements include, but are not limited to, statements about the timing of the anticipated acquisition of the manufacturing site, the amount and timing of planned investments in the site, expectations as to when the site will begin commercial scale production, potential benefits associated with the acquisition of the site, including the expected impact on future financial and operating results, and post-acquisition plans and intentions. The forward-looking statements contained herein are based on the current expectations and assumptions of NuVasive. The following important factors, among others, could cause actual results to differ materially from those set forth in the forward-looking statements: the satisfaction of conditions to closing the acquisition of the site; the risk that the site will require larger investments or take longer to build-out; and the risk that benefits associated with the acquisition may not be fully realized or may take longer to realize than expected. Additional factors that may affect future results are described in NuVasives news releases and periodic filings with the Securities and Exchange Commission. NuVasives public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.
# # #
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bekaert: Notice of Annual General Meeting of Shareholders
- Jimmy's Jazz & Blues Club Features 5x-GRAMMY® Award Nominated Jazz Pianist & Composer CHRISTIAN SANDS, a Steinway Artist, on Wednesday April 24 at 7:30 P.M.
- ArcelorMittal publishes convening notice for its Annual General Meeting of shareholders
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!